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CMV, Adenovirus (Ad) and EBV are viral pathogens causing mor-
bidity and mortality in patients after hematopoietic stem cell trans-
plantation (HSCT) and cord blood transplantation (CBT). We have
shown that adoptive immunotherapy with peripheral blood donor-
derived multivirus-specific Cytotoxic T Lymphocytes (mCTL) di-
rected against EBV, CMV and Ad can effectively prevent and treat
the clinical manifestations of these viruses after HSCT. We have
now extended these studies by expanding mCTL from umbilical
cord blood (CB) to restore cellular immunity to CMV, EBV and Ad
simultaneously after CBT. However, the development of mCTL for
patients undergoing CBT requires the priming and extensive expan-
sion of na€ıve T cells rather than the more limited and simple direct
expansion of pre-existingmemoryT cell populations from virus-expe-
rienced donors. We have developed a novel protocol utilizing an ini-
tial round of stimulation with autologous CB-derived dendritic cells
transduced with a recombinant Ad5f35 vector carrying a transgene
for the immunodominant CMV antigen, pp65 (Ad5f35pp65) in the
presence of IL12, IL15 and IL7. This is followed by 2 rounds of
weekly stimulation with autologous EBV-LCL transduced with the
same vector in the presence of IL15 and IL2. After 3 rounds of stim-
ulation, 2 CTL cultures generated for clinical use contained amean of
48% (range 24-72%) CD81, and 42% (range 11-72%) CD41 cells
with mean 30.5% (range 23-46%) CD45RA-/CD62L1 T cells. In
51Cr release and/or IFN-g ELISPOT assays, both mCTL lines
showed specific activity against CMV, EBV and Ad targets. So far
we have treated 2 patients in this phase I study, both on dose level 1
(5x106/m2). Patients received 1 infusion of CTL on day 63 post-
CBT. Only patient 1 is currently evaluable as patient 2 was infused
too recently to test. We observed a 10-fold increase in CMV-specific
T cells 5 weeks-post CTL. This patient was transiently positive for
CMV by PCR at 4 weeks post CTL but was negative within 16
days of receiving a second dose of mCTL with a corresponding rise
in CMV-specific CTL detected in the peripheral blood. The patient
became Ag1 for Ad in his stool associated with diarrhea which
resolved spontaneously without additional therapy. In summary, we
have developed a protocol for the generation of mCTL from CB: in-
fusion of small numbers of these cells increased virus-specificT cells in
the peripheral blood post CTL infusion dramatically earlier than
observed immune reconstitution post CBT.
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We have initiated a clinical trial in which patients receive infusions
of allogeneic T cells that are genetically modified with a gammaretro-
viral vector to express a chimeric antigen receptor (CAR) that recog-
nizes the B-cell antigen CD19. The first patient treated on this trial
was a 65 year-old man with chronic lymphocytic leukemia (CLL)
who relapsed after HLA-matched unrelated donor hematopoietic
stem cell transplantation. Following the relapse, the patient received
4 donor lymphocyte infusions (DLIs) with a maximum CD31 cell
dose of 2.9x107/kg and then a second stem cell transplant from the
original donor. An objective remission of the leukemia did not occur
after any of the DLIs or the second transplant. Five months after the
second transplant, whenhisCLLwas progressing, the patient received
an infusion of 6.2x107 (1x106 cells/kg) allogeneic anti-CD19-CAR-transduced T cells derived from his unrelated transplant donor.
Thirty-nine percent of the infused cells expressed the anti-CD19
CAR, and the cells produced interferong and IL-2 in a CD19-specific
manner. The patient did not receive any other therapy in conjunction
with the CAR-transduced T cells. From 6 to 12 days after the CAR-
transduced T cell infusion, the patient experienced fevers, fatigue,
mild hypoxemia, and intermittent mild hypotension. Increases in se-
rummagnesium, phosphorous, and uric acid consistent with tumor ly-
sis syndrome occurred. A decrease in cardiac left ventricular function
developed, which was improving at last follow-up. The patient’s blood
B cell count decreased from 286 cells/mL before the CAR-transduced
T cell infusion to 0 cells/mL 26 days after the cell infusion. Before the
CAR-transduced T cell infusion, CLL cells made up 80-90% of the
patient’s hypercellular bone marrow. A bone marrow biopsy per-
formed 26 days after the cell infusion showed a normocellularmarrow,
nearly absent B-lineage cells, and no evidence of CLL. CT scans re-
vealed a greater than 50%decrease in the size ofmultiple lymph nodes
after theCAR-transducedT cell infusion, but residual adenopathywas
present. CAR-transduced cells were not detected in the patient’s
blood by quantitative PCR during the first week after the T cell infu-
sion, but made up 0.98% of blood mononuclear cells 11 days after the
infusion. These results are encouraging for further development of
anti-CD19-CAR-expressing T cells as a treatment for relapse after
allogeneic stem cell transplantation.
22
ALLOGENEIC VIRUS-SPECIFIC T CELLS WITH HLA ALLOREACTIVITY DO
NOT PRODUCE GRAFT-VERSUS-HOST DISEASE IN HUMAN SUBJECTS
Melenhorst, J.J.1, Leen, A.M.2, Bollard, C.M.2, Quigley, M.F.3,
Price, D.A.3, Rooney, C.M.2, Brenner, M.K.2, Barrett, A.J.1,
Heslop, H.E.2 1National Heart, Lung, and Blood Institute, Bethesda,
MD; 2Baylor College of Medicine, Houston, TX; 3National Institute of
Allergy and Infectious Diseases, Bethesda, MD
We and others have recently established that T cell reactivity with
non-self HLA (HLA alloreactivity) arises not only from naive T cells
but also from the antigen-experienced T cell pool, including Epstein-
Barr virus (EBV) and cytomegalovirus (CMV)-specific T cells. Virus-
specific T cells could therefore mediate graft-versus-host disease
(GvHD) if infused into partially HLA mismatched recipients. We
reviewed our clinical experience with adoptive transfer of allogeneic
hematopoietic stem cell transplant donor-derived virus-specific T
cell lines in 153 recipients, including 73 partially HLA-mismatched
recipients. The degree of HLA mismatching varied from one allele
to a full haplotype. De novo GvHD did not develop after infusion of
cytotoxic T lymphocytes (CTL), and the incidence of GvHD reacti-
vation was 6.5% and not significantly different between recipients of
HLA matched or mismatched CTL. Thus, virus-specific CTL did
not mediate GvHD, even in recipients of partially matched CTL.
Next we analyzed the HLA alloreactivity of four donor-infused bivi-
rus-specific T cell lines, using activated T cells, that are known to
lack CMV and EBV antigen expression, as antigen presenting cells
(TAPC). We used a panel of 44 TAPC covering the most frequent
HLA class I and II alleles. The CTL lines were labeled with CFSE
and stimulated with TAPC for 6 hours, after which production of
TNFa and IFNg/IL-2 by CD41 and CD81 T cells in the CFSE-
positive fraction was analyzed by flow cytometry. All CTLs responded
to a number of TAPC, with some APC being recognized strongly.
The majority elicited only weak or no response from the CTLs. We
then assessed whether the CTLs recognized TAPC expressing the re-
cipient’s HLA alleles.We found moderate reactivity of the CTL with
1-5 TAPC expressing recipientHLA alleles. Taken together, our data
indicate that reactivity of virus-specific CTLs with hematopoietic
APC does not correlate with the risk of developing GvHD, and that
virus-specific CTL can safely be infused into HLA class I and/or II
mismatched recipients.
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